AQR Capital Management
ACHN

AQR Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

AQR Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-34,987
Closed -$144K – 2285
2016
Q4 		$144K Hold
34,987
– – ﹤0.01% 2187
2016
Q3 		$283K Buy
+34,987
New +$297K ﹤0.01% 2094
2015
Q2 		– Sell
-88,700
Closed -$875K – 2286
2015
Q1 		$875K Buy
88,700
+11,500
+15% +$144K ﹤0.01% 1477
2014
Q4 		$946K Buy
77,200
+35,900
+87% +$438K ﹤0.01% 1675
2014
Q3 		$412K Buy
+41,300
New +$383K ﹤0.01% 2021
2014
Q2 		– Sell
-700,600
Closed -$2.31M – 2618
2014
Q1 		$2.31M Buy
700,600
+45,400
+7% +$159K 0.01% 1217
2013
Q4 		$2.17M Buy
655,200
+645,055
+6,358% +$1.87M 0.01% 1306
2013
Q3 		$31K Hold
10,145
– – ﹤0.01% 2464
2013
Q2 		$83K Buy
+10,145
New +$77.4K ﹤0.01% 2301

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management's ACHN Position: Q1 2017 in Review

AQR Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2017, closing a stake of 34,987 shares — an estimated $144K sold.

AQR Capital Management first reported a position in ACHN in Q2 2013 and held it in 9 quarters. The position peaked at $2.31M in Q1 2014. 130 funds tracked by Wall St. Rank hold ACHN as of Q1 2017.

  • AQR Capital Management reported no remaining Achillion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • AQR Capital Management sold 34,987 Achillion Pharmaceuticals shares in Q1 2017, an estimated $144K.
  • AQR Capital Management first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • AQR Capital Management's Achillion Pharmaceuticals position peaked at $2.31M in Q1 2014.
  • 130 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2017.

Based on AQR Capital Management's 13F filing for Q1 2017, filed 15 May 2017.